1 Dupilumab-associated ocular surface disease: incidence, management and long-2 term sequelae. 3 4 5 Authors: Magdalena Z Popiela^{1,4}, Ramez Barbara¹, Andrew M J Turnbull^{1,5}, Emma Corden¹, 6 Beatrice Suarez Matinez-Falero¹, Daniel O'Driscoll ¹, Michael R Ardern-Jones^{1,3}, 7 Parwez N Hossain ^{1,2} 8 9 (Orcid ID: https://orcid.org/0000-0002-3131-2395) 10 11 ¹Eye Unit, Southampton General Hospital, Southampton UK 12 Affiliations: 13 ²Clinical Experimental Sciences, University of Southampton, 14 Southampton, UK 15 ³Dept of Dermatology, Southampton General Hospital, Southampton, UK16 ⁴ Eye Unit, St Bernard's hospital, Gibraltar 17 ⁵Bournemouth Eye Unit, Royal Bournemouth Hospital, Bournemouth, 18 19 UK20 21 Running title: Dupilumab -associated ocular surface disease 22 23 Key words: dupilumab -associated conjunctivitis, cicatrizing conjunctivitis, 24 dupilumab- associated ocular surface disease 25 26 27 Corresponding Author: 28 Professor Parwez Hossain 29 Eye Unit, 30 University of Southampton 31 Southampton General Hospital 32 Tremona Road 33 Southampton 34 SO16 6YD 35 Email: parwez@soton.ac.uk 36 Tel: +44 23 8120 4270

37 **Abstract** 38 39 **Objective** 40 To determine the incidence of ocular surface disease in patients with atopic dermatitis 41 (AD) treated with dupilumab at a tertiary, university hospital. To describe the features 42 of dupilumab-associated ocular surface disease, establish the need for treatment and 43 report any long-term effects on the ocular surface. 44 45 Methods 46 A retrospective analysis of consecutive patients treated with dupilumab for AD 47 between January 2017 and August 2019 was undertaken. Data was collected on 48 demographics, incidence and type of ocular disease features, natural history and 49 treatment. 50 51 **Results** 52 50% (14/28) patients developed ocular symptoms with a mean time of onset of 6.75 53 (+/- 6.1) weeks from starting dupilumab. 69% of these (9/13) were diagnosed with 54 conjunctivitis - associated with cicatrisation in two patients and periorbital skin 55 changes in four. Of these nine, four had prior history of atopic keratoconjunctivitis. 56 All were treated with topical steroids; two required additional ciclosporin drops. 67% 57 (6/9) patients developed chronic ocular inflammation requiring maintenance drops at 58 a mean of 16 (+/- 6.9) months of follow up. All patients had improvement in their AD 59 severity; only one patient discontinued dupilumab due to ocular side effects. 60 61

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Conclusion The rate of dupilumab-associated ocular surface disease was 32%. Periorbital skin changes and conjunctival cicatrisation were noted in association with conjunctivitis. Ocular surface disease improved on topical steroids and ciclosporin but 67% of patients needed on-going treatment. Patients should be referred to an ophthalmologist prior to starting dupilumab as a large proportion develops chronic ocular inflammation. Introduction Dupilumab is the first biologic approved for use in treatment of moderate to severe atopic dermatitis (AD). 1-5 Dupilumab targets interleukin (IL)-4 receptor blocking IL-4 and IL-13 signalling pathway. It has also shown promise in treatment of asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic oesophagitis.^{1,2} Dupilumab has been found to significantly improve signs and symptoms of AD and is considered a safe treatment for long-term use. 6 Conjunctivitis is a known side effect with rates in initial trials varying between 8.6% (CHRONOS) to 28 % (LIBERTY AD CAFÉ). Conjunctivitis is considered mild and self-limiting in the majority of cases. with fewer than 0.5% of patients suffering with a severe form necessitating drug cessation.² Current International Eczema Council recommendations allow for dupilumab to be started in patients with prior ocular surface disease and to continue dupilumab in the

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

event of conjunctivitis occurring. Prior history of ocular surface disease and more severe AD are considered risk factors for the development of dupilumab-associated conjunctivitis.^{8,9} Since the start of clinical use, apart from self-limiting conjunctivitis other ocular features have been described; severe follicular conjunctivitis ^{10,11}, limbal nodules ^{4,10}, blepharo-conjunctivitis ¹⁰⁻¹³, cicatricial ectropion ^{14,15}, keratitis ¹⁰ and dry eyes ¹⁶. This has led to the use of the term dupilumab-associated ocular surface disease to encompass various clinical presentations. ^{8,9,15} A much higher incidence of ocular surface problems has been reported in clinical practice than in the initial drug trials as high as 70% in one series. 4 No data is available on the longer-term effects of dupilumab on the ocular surface. Our study aimed to establish local incidence of dupilumab-associated ocular surface disease, describe its features, establish the need for treatment and identify any long-term sequelae. Methods The Health Research Authority and Health and Care Research Wales (HCRW) approval was granted in November 2019 (19/HRA/5882) for a retrospective case review of all patients developing dupilumab-associated eye disease at Southampton General Hospital- a large tertiary referral centre in the United Kingdom. Patients prescribed dupilumab between January 2017 and August 2019 were identified from the severe atopic dermatitis clinic in the dermatology department. Their details were checked in the electronic patient records to identify those who attended ophthalmology clinics. Data for patients who developed eye symptoms was

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

collected retrospectively in February 2020 to allow for at least six months of ophthalmic follow up. Presenting ocular symptoms, signs on initial review, treatment, visual acuity at first and last follow up and any side effects of topical therapy were noted. Long-term use of treatment was recorded. Eczema Severity and Index scores (EASI) were recorded at pre-treatment and at 16 weeks post dupilumab initiation, as well as the percentage of patients reaching 50 % and 75 % improvement in EASI at 16 weeks (EASI 50 and EASI 75 respectively). **Statistics** Because of only a few studies for reference, the study is classed as an exploratory research study. Data was analysed using descriptive statistics using The SAMPL Guidelines as reference (https://www.equator-network.org/wpcontent/uploads/2013/03/SAMPL-Guidelines-3-13-13.pdf) with the statistical tools within Microsoft Excel 2014 (Microsoft Corp., Redmond, WA). Logistic regression and Mann- Whitney U test were used to test for differences in demographic data between patients with and without ocular symptoms. Statistical significance was defined with a P value of equal to or less than 0.05. All statistical analyses were performed using SPSS software (version 20.0, IBM Corp, Armonk, NY, USA). **Results** 28 patients were prescribed dupilumab for AD between January 2017 and August 2019. 14 patients were referred to the ophthalmology department with symptoms of bilateral eye redness, soreness, itching and epiphora with a mean time of onset of 6.75 (+/- 6.1) weeks from starting dupilumab. One patient was lost to follow up with the

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

remaining 13 cases seen in the ocular surface clinic under the care of the ophthalmology department. There were no significant differences in demographic characteristics of patients treated with dupilumab who developed ocular symptoms and those who did not develop ocular symptoms. Four patients seen in the ophthalmology department showed reduced tear break up time (TBUT <10 seconds) with meibomian gland disease and were diagnosed as having evaporative dry eyes without signs of conjunctivitis. They were prescribed lubricating eye drops and given advice on lid hygiene. One patient received a course of Maxitrol ointment for eyelid disease. They were excluded from further analysis. Nine patients showed features of conjunctivitis on initial presentation with bilateral marked conjunctival redness [Figure 1]. Six patients displayed bilateral conjunctival papillary reaction and three had bilateral conjunctival follicular changes. Two patients showed limbal nodules similar in appearance to Trantas dots at initial visit. Two female patients, who were related, had associated conjunctival cicatrisation in the lower fornix and one showed scarring in the superior tarsal conjunctiva on initial presentation. One of these patients went on to develop progressive cicatrisation and a leukoplakic lesion in the lower fornix, confirmed on biopsy as pre-cancerous actinic keratosis with dysplasia [Figure 2]. Peri-ocular changes with cicatrising ectropion, punctal stenosis and periocular dermatitis were noted in four patients in association with conjunctivitis.

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

Mean time to development of self reported eye symptoms after the start of dupilumab therapy in the conjunctivitis group was 6 + -5.5 weeks. Patients were seen in the ocular surface clinic on average 8 +/- 5.2 weeks later. 44.4 % patients (4/9) had a past history of atopic keratoconjunctivitis prior to receiving dupilumab. Their ocular surface disease was stable at the time of dupilumab initiation with subsequent development of new symptoms of conjunctivitis. None were receiving active ophthalmic treatment at the time of starting dupilumab. Initial treatment in the eye clinic for dupilumab-associated conjunctivitis included topical steroids in all cases. Six patients received additional topical lubricant. Out of nine patients presenting with conjunctivitis, seven had a good response to topical steroids alone [Figure 3], two required additional topical ciclosporin 0.1% (Ikervis®, Santen Pharmaceuticals) to control symptoms. One patient was prescribed tacrolimus ointment to the eyelids by the dermatologist. 67% (6/9) patients were on maintenance topical steroid or steroid and ciclosporin combination at a mean of 16 +/- 6.9 months follow up. Two of these six (33%) had a prior history of atopic keratoconjunctivitis, which was quiescent at the time of starting dupilumab. The remaining three patients used topical steroid for 3-12 months with complete resolution of symptoms and signs of conjunctivitis. We have not noted any changes in visual acuity from first to last visit; mean visual acuity was recorded as 0.1 logMAR at both time points. No patients developed side effects due to prescribed drops. All patients had an improvement in their Eczema Area and Severity Index scores, with a 76% mean improvement in EASI score from

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

pre-treatment to 16 weeks follow-up in the conjunctivitis group. 89% of patients achieved EASI 50 (50 % improvement in EASI score) and 55.6% achieved EASI 75 (75% improvement in EASI score). One patient required additional therapy with methotrexate and one with topical steroids. Dupilumab was discontinued in one patient due to severe conjunctivitis with loss of eye-lashes (madarosis). **Discussion** Conjunctivitis is a known side effect of dupilumab, particularly affecting AD patients. 1,2 The LIBERTY AD CAFÉ study reported the highest incidence of dupilumab -associated conjunctivitis amongst initial trials (28%), attributed to higher awareness of this side effect amongst investigators. The CAFÉ trial reported conjunctivitis in 22.1% of patients, which was thought to be due to the high percentage of participants with severe AD and prior atopic keratoconjunctivitis, both of which are considered risk factors.^{8,9} In our series, we found a higher rate of dupilumab-associated conjunctivitis (32%) compared to landmark studies.² This is in keeping with other clinical reports of realworld outcomes. Dupilumab-associated ocular surface disease was reported in 43% and 70% by Nahum et al. and Ivert et al. respectively^{5,9}. These differences could be due to overall smaller numbers of patients included in the clinical reports compared to landmark studies. 2,4,5,10

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

Maudinet et al ¹⁰ reported features of dupilumab-associated conjunctivitis in keeping with our findings. In their series, 60% of patients presented with mild injection and papillary conjunctivitis and were treated with topical lubricants, whereas the remaining 40% had severe follicular conjunctivitis requiring topical steroid treatment. In our cohort we did not find that differentiating between papillary and follicular presentation was clinically relevant. All patient had severe bulbar conjunctiva injection, associated more commonly with papillary response, and all necessitated steroid therapy. Importantly, two patients in our study had cicatrising changes present in the lower fornix and subtarsal conjunctiva at presentation. These two patients were related, perhaps implicating a genetic predisposition for developing a more severe immune response to dupilumab. This could also be a result of their AD alone and / or due to the presence of chronic ocular inflammation. However, neither had a history of atopic keratoconjunctivitis (AKC) nor symptoms of chronic ocular surface problems requiring ophthalmic care prior to starting dupilumab. Another explanation for the severity of ocular surface inflammatory features in these two cases could be related to a delay in ophthalmic review between developing dupilumab related ocular symptoms and being seen in the ocular surface clinic. In one case this time delay was –five months. One of the patients affected by cicatrisation went on to develop a progressive leukoplakic lesion in the lower conjunctival fornix, which was confirmed histologically to be actinic keratosis with dyplasia - a precancerous lesion. This was

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

thought to be a result of life long immunosuppression and not solely a result of dupilumab use. This patient was continued on dupilumab due to good dermatological response. Further excisional biopsy with postoperative adjuvant treatment with Interferon alpha-2b drops was planned at last follow up. One patient (3.5%) in our series had to discontinue dupilumab due to severe conjunctivitis and loss of lashes (madarosis). Madarosis has not been described before and represents an extreme reaction to dupilumab. ^{2,5, 10-14} To our knowledge, there are two other case reports of conjunctival cicatrisation associated with dupilumab use. 12,17 Associated cicatrising ectropion, periocular dermatitis and punctal stenosis have been described more commonly making the term dupilumab- associated ocular surface disease rather than dupilumab-associated conjunctivitis more descriptive. ¹⁰⁻¹⁵ Dupilumab is also known to increase the risk of orofacial herpes simplex infection recurrence.^{2,5} Herpes simplex virus (HSV) uveitis while on dupilumab has been described with no reports of HSV keratitis.⁵ One patient in our series had previous history of HSV keratitis but did not develop any self-reported herpetic eye disease flare-ups whilst on dupilumab. No patients in our series were swabbed for the presence of HSV at the time of their acute presentation, so this cannot be ruled out for certain as a cause of their acute 'dupilumab- associated' conjunctivitis presentation. However, no patients demonstrated any of the typical features of herpes simplex keratitis and we consider HSV as the causative agent to be unlikely.

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

The aetiology of dupilumab-associated conjunctivitis is not fully understood but shares some common characteristics with atopic blepharoconjunctivitis and allergic eye disease - namely decrease in goblet cells, heightened OX40 ligand activity, eosinophilia and increased Demodex infestation due to changes in the ocular surface environment. 10,18-23 Allergic blepharokeratoconjunctivitis is common in AD with 32-56% of patients affected. 18,22-24 Previous history of atopic keratoconjunctivitis and more severe AD prior to dupilumab initiation have been implicated as risk factors for developing dupilumab-associated ocular surface disease. 8,9 In our series, 44.4% of patients had prior history of allergic eye disease and 50% went on to require longterm ocular treatment. All of our patients had improvement in ocular symptoms on topical steroids, which were the mainstay of the initial treatment. ²⁵ Topical steroids alone were sufficient at reversing signs and symptoms of acute conjunctivitis in 89% of patients. Two patients required additional ciclosporin drops to control their symptoms. Topical preparations of ciclosporin have been successfully used in treatment of ocular surface disease for many years. Ciclosporin is a calcineurin inhibitor that inhibits T-cell-mediated immune responses and has been shown to increase goblet cell numbers. ²⁶ Dupilumab targets IL-13 action and secondary depletion of goblet cells and mucin production in the conjunctiva could be responsible for dupilumab- associated conjunctivitis.²⁻⁵ Ciclosporin might be particularly useful in treatment of dupilumab-associated ocular surface disease as it could reverse some of the local immunological actions of dupilumab. Use of Ikervis (ciclosporin 0.1%) drops in dupilumab- associated ocular surface disease remains off label since Ikervis is approved for use in dry eyes.²⁸ In our series, Ikervis drops used twice a day were added to topical steroids with good clinical

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

outcomes. Use of tacrolimus^{4,8} and pimecrolimus²⁸ ointments to the eye lids has also been reported to improve dupilumab- associated ocular surface disease in other case series. Mean duration of follow up was 16 (+/- 6.9) months. A large proportion of our patients (67%) required continuation of topical immunosuppressive therapy to prevent flare-ups on discontinuation of drops. Akinlade et al. reported that 80% of patients had resolution of conjunctivitis while on dupilumab in clinical trials, but there was no mention of duration of symptoms, nor what therapy these patients received for treatment. It also leaves 20% of cases with on-going ocular surface inflammation while on dupilumab. These findings support our theory that dupilumab- associated conjunctivitis might not be just a one off event in all affected eyes. The drug might alter the ocular surface flaring up the susceptibility to chronic blepharoconjunctivitis in AD patients. Alternatively, a large percentage of AD patients considered for dupilumab have previously undiagnosed ocular surface inflammation. Clinically it is difficult to distinguish a blepharoconjunctivitis flare up from dupilumab- associated ocular surface disease as they share many similarities. ^{2,9-18} In the series of Maudinet et al.,64% of patients had previously undiagnosed blepharoconjunctivitis when examined prior to starting dupilumab. Interestingly, lower rates of dupilumabassociated conjunctivitis were observed in patients seen and treated by the ophthalmologist prior to starting the drug than in patients not seen by ophthalmologist prior to dupilumab therapy (13% versus 25% respectively). Current practice in the UK is that the ophthalmologist reviews patients after they develop ocular symptoms from dupilumab. Given that a large percentage of patients

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

require long-term ocular treatments, dupilumab is considered in a group of patients with high risk for ocular surface problems, and dupilumab-associated conjunctivitis can result in cicatrisation, our recommendation is that AD patients should be examined by the ophthalmologist prior to starting the drug. No patient in our cohort developed side effects due to topical therapy during the follow up and vision remained excellent. All had improvement in EASI scores. With the retrospective nature of our study and small sample it is impossible to say if our patients had pre-existing undiagnosed AKC or whether dupilumab sensitized their eyes to become chronically inflamed. Larger long-term prospective studies would be needed to answer this question. We also lack data on the exact duration of the acute dupilumab–associated conjunctivitis due to retrospective data collection. In our series of patients, those not requiring maintenance steroid drops used topical steroids between 3-12 months. In summary, dupilumab is used in patients who have a strong predisposition to chronic ocular surface problems. In our series, 32% were affected by acute dupilumab-associated ocular surface disease, which responded well to topical steroids with or without adjunctive topical ciclosporin. Dupilumab-associated conjunctivitis can lead to conjunctival cicatrisation and be associated with periocular skin changes, punctal stenosis and madarosis, making dupilumab- associated ocular surface disease a more useful, catch-all term. Dupilumab may unmask a predisposition to chronic ocular inflammation and a significant number of patients need long-term topical immunosuppressive therapy. Patients should be examined by the ophthalmologist

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

prior to starting dupilumab to optimise their ocular surface and arrange timely follow up to detect acute dupilumab-associated ocular surface disease more swift References 1. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). *Br J Dermatol*. 2018;178(5):1083 □ 1101. 2. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ et al. Conjunctivitis in dupilumab clinical trials. *Br J Dermatol*. $2019;181(3):459 \square 473.$ 3. Chu CY. Keeping an eye on the ocular problems in dupilumab clinical trials. Br J Dermatol. 2019;181(3):436-437 4. Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778 □ 1780. 5. Ivert LU, Wahlgren CF, Ivert L, Lundqvist M, Bradley M. Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis. Acta Derm Venereol. $2019;99(4):375 \square 378.$

356 6. Deleuran M, Thaci D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S et al. 357 Dupilumab shows long-term safety and efficacy in patients with moderate to severe 358 atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad 359 Dermatol. 2020;82(2):377-388. 360 361 7. Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran 362 M et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab 363 therapy - international eczema council survey and opinion. J Eur Acad Dermatol 364 *Venereol.* 2019;33(7):1224 \square 1231. 365 366 8. Treister AD, Kraff-Cooper C, Lio PA. Risk Factors for Dupilumab-Associated 367 Conjunctivitis in Patients With Atopic Dermatitis. *JAMA Dermatol*. 368 $2018;154(10):1208 \square 1211.$ 369 370 9. Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-371 induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical 372 presentation, risk factors for development and outcomes of treatment with tacrolimus 373 ointment. *Br J Ophthalmol*. 2020;104(6):776□779. 374 375 10. Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC. Ocular 376 Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis. *Ophthalmol* 377 Ther. $2019;8(3):485 \square 490$. 378

379 11. Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-Induced Follicular 380 Conjunctivitis. *Ocul Immunol Inflamm*. 2019;27(8):1339□1341. 381 382 12. Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing 383 Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed 384 Algorithm for Its Management. *JAMA Dermatol.* 2018;154(12):1485 \square 1486. 385 386 13. Paulose SA, Sherman SW, Dagi Glass LR, Suh LH. Dupilumab-associated 387 blepharoconjunctivitis. Am J Ophthalmol Case Rep. 2019;16:100550. 388 389 14. Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated 390 with dupilumab. *Am J Ophthalmol Case Rep.* 2017;7:120 \square 122. 391 392 15. Yamane MLM, Belsito DV, Glass LR. 393 Two differing presentations of periocular dermatitis as 394 a side effect of dupilumab for atopic dermatitis. Orbit. 2019;38(5):390-394. 395 396 16. Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-397 induced ocular surface disease (DIOSD): A novel case report. JAAD Case Rep. 398 $2018;5(1):34\square 36.$ 399 400 17.Liberman P, Shifera AS, Berkenstock M. Dupilumab-Associated Conjunctivitis in 401 Patients With Atopic Dermatitis. *Cornea*. 2020;39(6):784□786.

402

403 18. Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic 404 dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):478-485. 405 406 19. de Bruin-Weller M, Graham NMH, Pirozzi G, Shumel B. Could conjunctivitis in 407 patients with atopic dermatitis treated with dupilumab be caused by colonization with 408 Demodex and increased interleukin-17 levels?: reply from the authors. Br J Dermatol. 409 $2018;178(5):1220 \square 1221.$ 410 411 20. Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with 412 dupilumab be caused by colonization with Demodex and increased interleukin ☐17 413 levels? Br J Dermatol. 2018; 178 (5):1220. 414 415 21. Mennini M, Dahdah L, Fiocchi A. Two Phase 3 Trials of Dupilumab versus 416 Placebo in Atopic Dermatitis. N Engl J Med. 2017;376(11):1090 417 418 22. Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. 419 Incidence, prevalence, and risk of selected ocular disease in adults with atopic 420 dermatitis. J Am Acad Dermatol. 2017;77(2):280 \square 286 421 422 23. Bonini S. Atopic keratoconjunctivitis. *Allergy* 2004; 59 Suppl 78:71-3 423 424 24. Tuft SJ, Kemeny DM, Dart JK, Buckley RJ. Clinical features of atopic 425 keratoconjunctivitis. *Ophthalmology*. 1991;98(2):150 \square 158. 426

25. Aszodi N, Thurau S, Seegräber M, de Bruin-Weller M, Wollenberg A. Management of dupilumab-associated conjunctivitis in atopic dermatitis. *J Dtsch* Dermatol Ges. 2019;17(5):488-491. 26. Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 2010; 18(5): 352-61. 27. Hoy SM. Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease. *Drugs*. 2017;77(17):1909 \square 1916. 28. Sernicola A, Gattazzo I, Di Staso F, Giordano D, Capalbo A, Persechino F et al. Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin. Dermatol Ther. 2019;32(6):e13134. Figure captions Figure 1. Patient with acute dupilumab - associated conjunctivitis. Figure 2. Patient on dupilumab with progressive cicatrisation and leukoplakic lesion in lower fornix.

Figure 3. Patient from figure 1 after treatment with topical steroids.

453

454













